My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Incyte Corporation - Common Stock (NQ:INCY)

102.69 +5.38 (+5.53%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗

July 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo

July 18, 2022

From Incyte

Via Business Wire

The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine ↗

July 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss ↗

May 20, 2022

Via Benzinga

4 Analysts Have This to Say About Incyte ↗

May 04, 2022

Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter:

Via Benzinga

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance ↗

May 03, 2022

Via Benzinga

Incyte to Report Second Quarter Financial Results

July 12, 2022

From Incyte

Via Business Wire

Twitter And 3 Other Stocks Insiders Are Selling ↗

July 12, 2022

US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them ↗

July 11, 2022

Four pharmaceutical stocks, including three biotech movers, are making big moves.

Via Investor's Business Daily

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

Incyte: Q1 Earnings Insights ↗

May 03, 2022

Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

7 Defensive Stocks to Buy for a Bear Market ↗

June 27, 2022

As Wall Street gets ready for another earnings season, investors are increasingly chasing after defensive stocks to buy for a bear market.

Via InvestorPlace

Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock ↗

June 14, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate ↗

June 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Morning Brief: Top Financial Stories Dominating on Tuesday, June 14 ↗

June 14, 2022

CNBC

Via Benzinga

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy ↗

June 14, 2022

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

Via Benzinga

Insights On Incyte Corporation ↗

June 04, 2022

In the first quarter of 2022, Incyte Pharmaeuticals reported very strong quarterly results, highlighted by the launch of Opzelura. The launch continues to perform well, with Q1'22 sales of $13 million...

Via Talk Markets

Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting

May 26, 2022

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

May 24, 2022

From Incyte

Via Business Wire

Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review ↗

May 20, 2022

A confirmed market uptrend is reeling as inflation's pain bites.

Via Investor's Business Daily

Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted ↗

May 13, 2022

Via Benzinga

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas ↗

May 13, 2022

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The...

Via Benzinga

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now ↗

May 13, 2022

The race is on in eczema treatment as the biggest name faces new rivals.

Via Investor's Business Daily

FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19 ↗

May 11, 2022

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients.

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

May 05, 2022

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

May 04, 2022

From Incyte

Via Business Wire

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 03, 2022

From Incyte

Via Business Wire

Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M ↗

May 02, 2022

Global Cord Blood Corporation (NYSE: CO) will acquire Cellenkos Inc and the rights to develop and commercialize all of its existing and future products worldwide.

Via Benzinga

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.